STOCK TITAN

AYTU BIOPHARMA (AYTU) SEC Filings

AYTU NASDAQ

Aytu BioPharma, Inc. filings document a Nasdaq-listed pharmaceutical issuer with common stock trading under AYTU and a business centered on EXXUA, ADHD treatments, and other prescription products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor materials, and material agreements affecting the company's financing and capital structure.

The filing record also includes definitive proxy disclosures covering board matters, executive compensation, equity awards, and shareholder voting items. Other 8-K disclosures address loan and security agreement amendments with Aytu operating subsidiaries, warrant-related accounting and stockholder-approval language, and classification issues affecting reported liabilities or equity.

Rhea-AI Summary

Aytu BioPharma, Inc. (AYTU) disclosed preliminary communications about a planned tender offer for all of its outstanding common stock. RoseApollo Merger Sub, Inc., a wholly owned subsidiary of Rosemont Pharmaceuticals Holdings, Inc., plans to make the offer under a merger agreement dated November 16, 2026. The tender offer has not yet commenced. When it begins, Rosemont and RoseApollo intend to file tender-offer materials with the SEC, and Aytu says it will then file a solicitation/recommendation statement. The current communication is informational, not an offer to purchase or a recommendation. Identified uncertainties include the offer’s timing, how many stockholders tender shares, whether offer and merger conditions are satisfied or waived, and events that could terminate the merger agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
-
Rhea-AI Summary

AYTU BioPharma, Inc. is party to an Agreement and Plan of Merger dated November 16, 2026, with Rosemont Pharmaceuticals Holdings, Inc. and RoseApollo Merger Sub, Inc., the parent’s wholly owned subsidiary. Rosemont plans to cause Merger Sub to commence a tender offer for all outstanding AYTU common shares; the offer has not yet commenced. When it begins, the offerors plan to file tender offer materials on Schedule TO, and AYTU plans to file a Schedule 14D-9 recommendation statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.15%
Tags
ownership
-
Rhea-AI Summary

AYTU BioPharma reported net revenue of $14.842 million for the three months ended September 30, 2026, up 6.9% from $13.888 million a year earlier. EXXUA generated $4.9 million; ADHD Portfolio revenue fell to $7.737 million from $13.156 million, while Pediatric Portfolio revenue rose to $2.205 million from $0.715 million. Gross profit margin was 64%, compared with 66%.

AYTU recorded a $3.881 million net loss, versus $1.965 million net income a year earlier. Operating activities used $275,000 in cash. Cash and cash equivalents were $25.494 million as of September 30, 2026, with $5.1 million available under the revolving credit facility. Management believes cash, operating cash flows and credit availability will fund operations and obligations for at least 12 months.

On November 16, 2026, AYTU entered an agreement for Rosemont to acquire all outstanding common shares through a $2.70-per-share cash tender offer, followed by a merger making AYTU a wholly owned subsidiary. Closing is subject to customary conditions, including tender of a majority of outstanding shares; the parties expect it by calendar year-end, subject to satisfaction or waiver of conditions. Completion is expected to repay and terminate the Eclipse Agreement, including applicable early termination fees, and accelerate unrecognized stock-based compensation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.15%
Tags
quarterly report
Rhea-AI Summary

Aytu BioPharma (AYTU) reported fiscal 2027 first-quarter net revenue of $14.8 million, up 6.9% from $13.9 million a year earlier. EXXUA net revenue was $4.9 million, up 24.5% from the prior quarter, while prescriptions rose 32.5% sequentially to 4,400. ADHD Portfolio revenue was $7.7 million versus $13.2 million a year earlier; Pediatric Portfolio revenue was $2.2 million versus $0.7 million.

Net loss was $3.9 million, compared with $2.0 million net income a year earlier, and Adjusted EBITDA loss was $2.6 million versus $0.6 million. Cash and cash equivalents totaled $25.5 million at September 30, 2026.

Aytu also entered a definitive agreement under which Rosemont would acquire it through a $2.70-per-share cash tender offer, followed by a merger. Stated total consideration is approximately $56 million on a fully diluted basis, calculated using the treasury stock method. The offer has not commenced. Completion is expected by the end of calendar 2026, subject to customary conditions, including tender of a majority of Aytu’s outstanding shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.15%
Tags
current report
-
Rhea-AI Summary

AYTU agreed to be acquired by Rosemont Pharmaceuticals Holdings in a two-step transaction: RoseApollo Merger Sub, Parent’s wholly owned subsidiary, will make a cash tender offer for all AYTU issued and outstanding common shares at $2.70 per share, then merge into AYTU if the offer is consummated. The offer has not commenced; it is to begin as promptly as practicable and no later than 10 business days after November 16, 2026.

The offer is subject to conditions, including valid tenders plus shares already beneficially owned by Parent, Purchaser and their wholly owned subsidiaries representing a majority of AYTU shares outstanding at consummation. The merger is to follow under Section 251(h) of the Delaware General Corporation Law, without a stockholder meeting or vote, after acceptance of tendered shares and satisfaction or waiver of limited conditions. AYTU’s board and special committee unanimously recommended the offer. Certain officers, all directors and certain stockholders agreed to tender their shares under support agreements. AYTU may owe a $2.4 million termination fee in specified circumstances.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.15%
Tags
merger
-
Rhea-AI Summary

AYTU agreed to be acquired by Rosemont Pharmaceuticals Holdings in a two-step, all-cash transaction at $2.70 per share, net to sellers without interest and subject to tax withholding. Rosemont’s wholly owned subsidiary will commence a tender offer as promptly as practicable and no later than 10 business days after the November 16, 2026 agreement; the offer has not yet commenced. AYTU’s board and special committee unanimously recommended that stockholders accept and tender their shares.

Completion is conditioned, among other things, on validly tendered shares, together with shares beneficially owned by Rosemont and related subsidiaries, representing a majority of AYTU’s outstanding shares. Another condition requires no more than 15% of warrant-underlying shares to remain outstanding without being exercised and tendered or otherwise terminated. There is no financing condition. After the offer, a second-step merger would pay the same price for eligible remaining shares without a stockholder vote, subject to customary conditions and appraisal rights. Closing is anticipated in late December 2026, subject to conditions.

The agreement permits termination if the offer is not completed by February 14, 2027. AYTU may owe Rosemont a $2.4 million termination fee in specified circumstances, including certain recommendation changes or a qualifying competing transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.15%
Tags
current report
Rhea-AI Summary

Aytu BioPharma, Inc. is asking stockholders at its 2027 annual meeting, scheduled for December 10, 2026, to elect five directors and vote on four other proposals: add 500,000 shares to the 2023 Equity Incentive Plan, bringing its reserve to 1,000,000 shares; approve a new 2027 Employee Stock Purchase Plan (ESPP) with 500,000 shares reserved; ratify Grant Thornton as auditor for fiscal 2027; and cast a nonbinding advisory vote on 2026 executive compensation. The board recommends voting for each proposal. Stockholders of record on October 13, 2026, are eligible to vote; 10,868,208 common shares were outstanding that day.

If approved, no ESPP purchase rights may be exercised before stockholder approval, and its first offering period would start on the first trading day on or after July 1, 2027. The proposed ESPP purchase price applies a 15% discount to the lower of the offering-date or purchase-date value. If Proposals 2 and 3 are both approved, the proxy’s table shows fully diluted overhang of 4.1%. Grant Thornton’s audit fees were $705,000 for fiscal 2026, compared with $849,000 for fiscal 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
proxy
-
Rhea-AI Summary

AYTU BioPharma, Inc. (AYTU) is a CNS-focused pharmaceutical company that has repositioned around commercial-stage prescription products, led by EXXUA, an FDA-approved extended-release antidepressant for adult major depressive disorder. The company exited its Consumer Health business in fiscal 2025 and now operates as a single commercial segment.

In fiscal 2026 AYTU generated $57.6 million in net revenue, including $6.6 million from the successful launch of EXXUA, while its ADHD portfolio produced $45.8 million and its pediatric product Karbinal ER $5.1 million amid reduced promotion. The company reported a $14.3 million net loss and an accumulated deficit of $347.8 million, but is prioritizing operational efficiencies and higher-margin products to pursue positive operating cash flow.

AYTU’s capital structure includes a term loan and revolving credit facility under the Eclipse Agreement, both maturing in 2029, and a June 2025 equity raise that delivered $14.8 million in net proceeds to support EXXUA commercialization. Key risks include double‑digit revenue declines in ADHD and pediatric portfolios, high customer concentration, a Paragraph IV challenge to Adzenys, extensive regulatory and compliance obligations, and the possibility of Nasdaq delisting if listing standards are not maintained.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
annual report
-
Rhea-AI Summary

Aytu BioPharma, Inc. (AYTU) reported fiscal 2026 Q4 and full-year results highlighting early EXXUA traction and mixed legacy portfolio trends. Q4 2026 net revenue was $16.1 million, up 6.4% from $15.1 million, with EXXUA contributing $3.9 million and the ADHD Portfolio $10.4 million.

Q4 net loss was approximately break-even at less than $0.1 million, versus a $19.8 million loss a year earlier, and Adjusted EBITDA was $0.5 million. For fiscal 2026, net revenue was $57.6 million versus $66.4 million, and net loss was $14.3 million versus $13.6 million. Full-year Adjusted EBITDA declined to -$3.7 million from $9.2 million as the company increased EXXUA commercialization investments.

EXXUA generated $6.6 million in fiscal 2026 net revenue, including 3,323 prescriptions in Q4, up about 138% from 1,398 in Q3. As of June 30, 2026, cash and equivalents were $26.3 million and stockholders’ equity was $35.3 million, aided by reclassification that reduced derivative warrant liabilities to $1.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
current report
Rhea-AI Summary

Aytu BioPharma, Inc. has a significant shareholder, Laurence W. Lytton, and the Lytton-Kambara Foundation jointly reporting beneficial ownership of Aytu common stock. Each reports 545,946 shares beneficially owned, representing 4.99% of the common stock, based on 10,733,208 shares outstanding as of April 30, 2026. All voting and dispositive powers are reported as shared, with no sole power held by either reporting person. The holdings include existing common shares and warrants to purchase additional shares, all subject to a 4.99% beneficial ownership limitation. The parties also provide a joint filing agreement covering their Schedule 13D or 13G submissions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
ownership

FAQ

How many AYTU BIOPHARMA (AYTU) SEC filings are available on StockTitan?

StockTitan tracks 50 SEC filings for AYTU BIOPHARMA (AYTU), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for AYTU BIOPHARMA (AYTU)?

The most recent SEC filing for AYTU BIOPHARMA (AYTU) was filed on November 20, 2026.